|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0031809,
umls-concept:C0205179,
umls-concept:C0205460,
umls-concept:C0205464,
umls-concept:C0249042,
umls-concept:C0280100,
umls-concept:C0764377,
umls-concept:C0971473,
umls-concept:C1280500,
umls-concept:C1420841,
umls-concept:C2003941,
umls-concept:C2698300,
umls-concept:C2917367
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2007-8-13
|
|
pubmed:abstractText |
Cilengitide, an antiangiogenic agent that inhibits the binding of integrins alpha(nu)beta(3) and alpha(nu)beta(5) to the extracellular matrix, was studied at two dose levels in cancer patients to determine the optimal biological dose.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:BaronAA,
pubmed-author:BascheMM,
pubmed-author:ColevasDD,
pubmed-author:DavisDD,
pubmed-author:EckhardtS GSG,
pubmed-author:GallemannDD,
pubmed-author:GoriHH,
pubmed-author:GustafsonDD,
pubmed-author:HariharanSS,
pubmed-author:HolderWW,
pubmed-author:McConkeyDD,
pubmed-author:MorrowMM,
pubmed-author:O'BryantC LCL,
pubmed-author:ZaniAA
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1400-7
|
|
pubmed:meshHeading |
pubmed-meshheading:17693653-Angiogenesis Inhibitors,
pubmed-meshheading:17693653-Apoptosis,
pubmed-meshheading:17693653-Cell Adhesion Molecules,
pubmed-meshheading:17693653-Dose-Response Relationship, Drug,
pubmed-meshheading:17693653-Endothelial Cells,
pubmed-meshheading:17693653-Gene Expression,
pubmed-meshheading:17693653-Humans,
pubmed-meshheading:17693653-In Situ Nick-End Labeling,
pubmed-meshheading:17693653-Integrin alphaVbeta3,
pubmed-meshheading:17693653-Integrins,
pubmed-meshheading:17693653-Neoplasms,
pubmed-meshheading:17693653-Receptors, Vitronectin,
pubmed-meshheading:17693653-Snake Venoms
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.
|
|
pubmed:affiliation |
University of Colorado Cancer Center, Aurora, CO 80045, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I,
Research Support, N.I.H., Extramural
|
